The patients who have been diagnosed with advanced or metastatic solid tumours, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no standard curative therapy exists were enrolled in the study.
Oncolytics COO Dr. Matt Coffey said the company has completed the enrolment of the technical study examining cyclophosphamide’s potential to modulate the immune system’s response to Reolysin.
"Studies of this type help to advance our understanding of the interaction between the immune system and our product," Dr. Coffey added.
The primary objective of the open label study is to determine the minimum effective immunomodulatory dose of cyclophosphamide necessary to obtain successful immune modulation.
The secondary objectives of the dose-escalating, 36-patient trial include assessing the safety profile of the combination and gathering any evidence of antitumor activity.